The Biden administration’s proposal to expand Medicare and Medicaid coverage for anti-obesity medications like Wegovy and Ozempic marks a significant shift in healthcare policy. By reinterpreting long-standing rules, the Centers for Medicare and Medicaid Services (“CMS”) now recognize obesity as a chronic disease, paving the way for coverage of drugs aimed at reducing and maintaining weight loss. While this policy aligns with the evolving medical consensus on obesity management, it also creates a complex landscape for pharmacies—offering new opportunities while presenting considerable risks.
Opportunities for Pharmacies
Pharmacies, especially those specializing in chronic disease management, are well-positioned to benefit from this policy change.
- Increased Prescription Volume
With millions of Americans potentially gaining access to anti-obesity medications, pharmacies may see a significant uptick in prescription volume (provided that pharmacies can maintain sufficient inventory of these drugs). This is particularly true as coverage under Medicare and Medicaid often sets a precedent for private insurers and employer-sponsored plans to follow. - Specialty Pharmacy Growth
Pharmacies that provide specialized services, including patient counseling, medication adherence programs, and chronic disease management, can leverage their expertise to play a central role in obesity care. - Provider Partnerships
Pharmacists are uniquely positioned to collaborate with healthcare providers in implementing these treatments. By providing medication education and monitoring, pharmacies can strengthen their partnerships with providers and improve patient outcomes.
Risks and Shortfalls
While the opportunities are notable, pharmacies must also navigate significant challenges in this new landscape.
- Increased PBM Audit Activity
The high cost of medications like Wegovy and Ozempic makes claims for these drugs a prime target for Pharmacy Benefit Manager (“PBM”) audits. Pharmacies can expect heightened scrutiny on issues such as:- Prescription Legitimacy: Verifying that prescriptions meet payer requirements.
- Coverage Compliance: Ensuring claims align with CMS criteria for obesity treatment.
- Manufacturer Coupon Use: PBMs frequently flag claims involving manufacturer discounts, which can lead to recoupment demands and additional penalties.
- Compliance Complexities
Pharmacies must maintain strict adherence to evolving state and federal regulations, payer-specific guidelines, and compliance standards for Medicaid and Medicare claims. Missteps in handling claims, particularly regarding coupon programs or eligibility requirements, could expose pharmacies to financial and legal risks. - Economic Sustainability
The expansion of coverage for high-cost drugs places significant strain on federal and state budgets. Pharmacies could face repercussions through stricter cost-containment measures, such as lower reimbursement rates and formulary restrictions. These measures may challenge pharmacies’ profitability and operational efficiency.
Balancing Opportunity and Risk
This policy shift offers an unprecedented opportunity for pharmacies to expand their role in obesity care. However, it also introduces risks that demand careful navigation. To succeed, pharmacies should take proactive steps, including:
- Audit Preparedness
Implementing robust compliance protocols and maintaining meticulous documentation to minimize the impact of PBM audits. - Monitoring Policy Changes
Staying ahead of regulatory and payer updates to ensure continued eligibility for claims and alignment with best practices. - Advocacy for Balanced Solutions
Advocating for sustainable healthcare policies that prioritize patient access to care without disproportionately burdening pharmacies or taxpayers.
The expansion of anti-obesity drug coverage represents both a transformative opportunity and a call for vigilance. Pharmacies must adapt quickly to the changing environment, balancing the promise of growth with the challenges of compliance and sustainability. By staying informed and proactive, pharmacies can position themselves as indispensable players in the evolving healthcare landscape.
How Frier Levitt Can Help
Regardless of the size of your pharmacy or the financial stakes involved, Frier Levitt is here to stand by you in challenging PBM overreach. Our experienced life sciences attorneys offer proactive guidance to help your pharmacy prepare for audits and are ready to take an aggressive stance to protect your rights when adverse PBM actions arise. If you have questions about PBM audits, need assistance navigating compliance challenges, or are facing unjust PBM actions, contact Frier Levitt today to speak with an attorney dedicated to advocating for your pharmacy’s success.
